For research use only. Not for therapeutic Use.
GDC-0994 (Cat.No:I001753) is a small-molecule inhibitor used in cancer research. It targets the mitogen-activated protein kinase kinase 1 (MEK1) enzyme, which plays a critical role in cell growth and proliferation pathways. GDC-0994 has shown potential in inhibiting the growth of cancer cells and is being studied for its therapeutic applications in various types of cancers.
| Catalog Number | I001753 |
| CAS Number | 1453848-26-4 |
| Synonyms | (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one |
| Molecular Formula | C21H18ClFN6O2 |
| Purity | ≥95% |
| Target | MEK1/2 |
| Solubility | DMSO: ≥ 35 mg/mL |
| Storage | Store at -20°C |
| IC50 | 1.1 nM/0.3 nM(ERK1/ERK2) [1] |
| IUPAC Name | 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one |
| InChI | InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1 |
| InChIKey | RZUOCXOYPYGSKL-GOSISDBHSA-N |
| SMILES | O=C(N([C@H](CO)C1=CC(F)=C(Cl)C=C1)C=C2)C=C2C3=NC(NC4=CC=NN4C)=NC=C3 |
| Reference | 1:J Med Chem. 2016 Jun 23;59(12):5650-60. doi: 10.1021/acs.jmedchem.6b00389. Epub 2016 Jun 7. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.Blake JF,Burkard M,Chan J,Chen H,Chou KJ,Diaz D,Dudley DA,Gaudino JJ,Gould SE,Grina J,Hunsaker T,Liu L,Martinson M,Moreno D,Mueller L,Orr C,Pacheco P,Qin A,Rasor K,Ren L,Robarge K,Shahidi-Latham S,Stults J,Sullivan F,Wang W,Yin J,Zhou A,Belvin M,Merchant M,Moffat J,Schwarz JB, PMID: 27227380 DOI: 10.1021/acs.jmedchem.6b00389 </br><span>Abstract:</span> The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by upstream oncogenic signaling. While targeting upstream nodes with RAF and MEK inhibitors has proven effective clinically, resistance frequently develops through reactivation of the pathway. Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (22), an orally bioavailable small molecule inhibitor selective for ERK kinase activity. |
